| --- | --- | --- | --- | |-----------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | PacBio Q2 2024 Earnings | | | | | | | | | | Presentation August 7, 2024 Second Quarter 2024 Earnings Call | | | | | | | | | | | | | | | | | | | | | | | | 1 Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Jack Meehan - Nephron Research Madeline Mollman - Wolfe Research Sung Ji Nam - Scotia Bank Matt Sykes - Goldman Sachs Operator Good day and welcome to the PacBio Second Quarter 202 ...

PacBio Announces Second Quarter 2024 Financial Results MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) - - PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: • Revenue of $36.0 million compared with $47.6 million in the prior-year period. TM • Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. Instrument revenue in the second quarter of 2024 included 24 Revio sequencing systems. • Consumables revenue ...

Pacific Biosciences of California (PACB) ended the recent trading session at $2.05, demonstrating no swing from the preceding day's closing price. This change was narrower than the S&P 500's 0.5% loss on the day. Elsewhere, the Dow saw an upswing of 0.5%, while the tech-heavy Nasdaq depreciated by 1.28%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.91 per share and revenue of $177.46 million, indicating changes of +18.02% and -11.5%, respectively, compared to the previou ...

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.88, marking a +1.62% move from the previous day. This change outpaced the S&P 500's 2.32% loss on the day. Meanwhile, the Dow experienced a drop of 1.25%, and the technology-dominated Nasdaq saw a decrease of 3.64%. Investors will be eagerly watching for the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 7, 2024. The company ...

The new lab at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich serves as a strategic hub for Novogene's European operations and builds on its global network of labs across the UK, US, Singapore, Japan and China. The addition of the Revio will complement Novogene's existing sequencing portfolio, giving customers answers where other technologies have been unable to, due to depth or accuracy limitations. As well as rare disease and cancer research, Novogene anticipates high demand for the ...

MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics expertise, working with a wide range of leading research institutions, clinical and commerc ...

The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2 Earnings Call." Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically c ...

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio products are provided for Research Use Only. Not fo ...

Pacific Biosciences of California (PACB) , popularly known as PacBio and Form Bio, a provider of advanced computational life sciences technology, recently collaborated and announced a range of new initiatives intended toward advancing and unifying the Adeno-associated virus (AAV) industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and ...